11/5/2026

speaker
Danielle
Conference Operator

Good day and welcome to the Joint Corporation Third Quarter 2026 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Richard Land with Alliance Advisors. Please go ahead.

speaker
Richard Land
Alliance Advisors

Thank you, Danielle, and good afternoon, everyone. Joining us on the call today are President and CEO Sanjiv Razdan and CFO Scott Bowman. Please note we are using a slide presentation that can be found on the Joint's IR website. This afternoon, the Joint Corp. issued a press release for the third quarter ended September 30, 2026. The release is available on the company's website. Please be advised that today's discussion, including any financial and related guidance to be provided, consists of forward-looking statements as defined by securities laws. These statements are based on information currently available to us and involve risks and uncertainties that could cause actual future results, performance, and business prospects and opportunities to differ materially from those expressed in or implied by these statements. Some important factors that could cause such differences are discussed in the risk factor section of the Joint Corp's violence with the Securities and Exchange Commission. Overlooking statements speak only as of the date the statements are made, and the company assumes no obligation to update them except to the extent required by applicable securities laws. Management uses non-GAAP financial measures such as EBITDA, adjusted EBITDA, and free cash flow. The description of these measures is included in the press release issued earlier this afternoon, and reconciliations to the most directly comparable gap measures are included in the appendix to the presentation and press release, both available in the investors tab of our website. With that, I'll now turn the call over to Sanjiv Razdan. Sanjiv, please go ahead.

speaker
Sanjiv Razdan
President and Chief Executive Officer

Thank you, Richard, and good afternoon, everyone. Our third quarter results show that the actions we have taken to strengthen patient engagement and Reshape, our operating model, are beginning to work together. We are encouraged by progress in several of our leading patient metrics while recognizing that the consumer environment continues to weigh on spending and our comparable sales. Our active membership count grew during the quarter as our initiative to win back lapsed patients gained momentum. Patients are also staying with us longer and spending more over the course of their relationship with the joint, supporting higher patient lifetime value. At the same time, ongoing pressure on consumer spending led to fewer new patients and lower average patient spend per month, which weighed on comp sales. Comp sales were negative 1.9% in the third quarter, Improving from negative 2.8% in the second quarter and negative 4.2% in the first quarter. Financially, we continue to see the benefits of our Capital Light model with revenue growth and stronger profitability from continuing operations. Scott will walk through the results in more detail. Overall, we are pleased to see that the underlying membership and lifetime value trends are improving and our franchisor model is producing stronger profitability. Our updated outlook takes a realistic view of the consumer while our focus remains squarely on returning to positive comp sales. Turning to slide five, let me briefly highlight our third quarter financial results. Revenue increased 1% year over year to 13.6 million. System-wide sales were $123.3 million, down 3.1% from the prior year period, while comp sales were negative 1.9% versus negative 2.8% in the second quarter. Net income from continuing operations increased by $1.2 million to $1.5 million compared with $290,000 in the third quarter of 2025. Adjusted EBITDA from continuing operations increased by $900,000 to $2.3 million, compared with $1.4 million in the prior year period. Together, these results reflect the improving operating leverage of our franchisor model. Turning to slide 6. Now, turning to membership and patient metrics, we saw encouraging progress during the quarter. Conversion and retention improved, supporting active membership growth. Active members per clinic increased compared with prior year period and compared with the second quarter of 2026. We also increased the average number of months per active member and total dollars per active member, improving patient lifetime value. In short, members are staying with us longer and spending more over their relationship with the joint. However, lower average patient spend per month partially offset these benefits, which is why the underlying gains have not yet translated into positive comps. While the longer term value of the patient relationship is improving, near term spending remains under pressure. Our focus remains on building the active member base and delivering value in a way that supports patients and the franchisees through the current environment. Turning to slide seven, we are pursuing growth in three ways. Improving comp sales, expanding our clinic network, and responding to growing consumer interest in longevity and health span. I'll start with comp sales, where our initiatives follow the patient journey, attracting new patients, converting them to members, and keeping them engaged longer. First, we are improving new patient acquisition by strengthening lead management. We are on track to launch a new AI-powered lead management platform supported by six AI agents in January 2027. We believe it can begin contributing to com sales growth during 2027. Among other things, it has the capability to follow up on leads, book appointments, and answer frequently asked questions. This builds on our broader digital efforts to help more patients find the joint and understand how we can help. Our SEO and AI visibility work continues to support online discovery, with our AI visibility score remaining in the mid-70s ahead of competitors across key search topics. We also recently updated our website to highlight our doctors' experience and address common patient questions about pain and specific conditions helping turn online interest into clinic visits. Second, we are improving conversion through flexible membership plans. Our flexible membership options give patients more choice while preserving the affordability and accessibility of the joint model. Lowering the barrier to joining helps us convert more first-time visitors into members and gives existing members a reason to stay rather than cancel. Third, we are improving retention and winning back lapse patients. These patients already know the joint and have benefited from our membership model when they were previously in discomfort. During the third quarter, targeted outreach and promotions helped drive higher lapse patient win back compared with the prior year period, supporting active membership growth. The cost to bring back a lapse patient is significantly lower compared to the cost to acquire someone new to the joint. And finally, we are also improving member engagement by personalizing the experience for our MVPs or most valuable patients to increase their lifetime value. During the third quarter, we launched new app features addressing some of their most requested needs including adding clinic wait times, which doctor is on schedule in app registration along with birthday and membership anniversary recognition. Turning to slide eight. Beyond improving comp sales, we are also focused on expanding our clinic network using three strategies. First, we are improving new clinic economics. Our 2025 clinic class continues to outperform prior year cohorts and clinics opened in 2026 are performing even better. For example, our recent average time to break even for new 2026 clinics is approximately three months compared with approximately 18 months historically. This performance has been supported by more disciplined site selection and more rigorous pre-opening protocols. Second, we are attracting franchisees with the capacity to expand. We are targeting well-capitalized, experienced multi-site operators while supporting strong existing franchisees that are interested in adding locations. Our compact clinic footprint, low capital requirement, and lean staffing model are well suited to multi-unit ownership. And third, we are advancing development in reacquired regional developer territories. Buying back RD rights allows us to support franchisees directly. strengthen clinic performance and recruit operators for specific markets. Across the five territories that we acquired this year, we have identified potential for more than 150 additional clinics providing a meaningful development opportunity. Supporting all three, we recently signed with a franchise broker network to accelerate franchisee recruitment and drive new clinic openings. Turning to slide nine. Our third growth opportunity is to elevate the patient experience and our care offerings to align with growing consumer interest in longevity, health span, mobility, and non-invasive whole body care. As Americans live longer, there is a growing consumer need for improving health span. We believe that the joint model of improving patient mobility and lowering pain is relevant to this need. We are using consumer research to better understand patient needs and personalize the experience, which is helping us to match our offerings with patients' demands. Pain relief and improved mobility remain central to our message alongside the quality of the patient experience. Our goal is to help patients get back to doing the things they love and encourage long-term engagement. We are in early stages of testing proprietary clinical care protocols with measurable health outcomes. This includes mobility scores, giving patients clear visibility into their improvement in mobility, pain, and functional health over time, all with the intent of providing our patients with more personalized care and the motivation for consistent ongoing care. And finally, We are piloting complementary retail offerings including orthotics and nutritional supplements as we evaluate additional ways to address patient needs and supporting our positioning around mobility and whole body care. Let's turn to slide 10. Now, moving on to re-franchising efforts. Supporting these growth priorities is our transition to a capital life, pure play franchise or model. With re-franchising substantially complete, our management team is focusing more directly on franchisee support, patient acquisition, and network development with less operational complexity from company-owned clinics. The ownership transfers for our 15 remaining company-owned or managed clinics continue to progress as lease assignments and related steps are completed. Once those transfers are complete, we will have no remaining company-owned or managed clinics. The benefits of the model are increasingly visible in our results. Through the first nine months of 2026, net income from continuing operations improved to $2.3 million from a net loss of $1.2 million a year ago. while adjusted EBITDA from continuing operations increased to $5.9 million from $1.5 million. This structure is helping to improve margins, profitability and cash generation from continuing operations. While we still have work to do to restore consistent system-wide growth, the business is leaner and better positioned to convert future growth into earnings and cash flow. With that, I'll turn it over to Scott.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation